In patients with KIT exon 11 mutations particularly.

Stable disease at 16 weeks can be an essential milestone for refractory sufferers so I believe these early medical responses to ponatinib are encouraging.’.. ARIAD reviews data from Iclusig Stage 2 trial in adult patients with gastrointestinal stromal tumors ARIAD Pharmaceuticals, Inc. The original data present that ponatinib provides anti-tumor activity in patients with advanced GIST, in patients with KIT exon 11 mutations particularly, after failing of at least one prior tyrosine kinase inhibitor . The primary endpoint for the trial, clinical benefit rate at 16 weeks for patients with KIT exon 11 mutations, was 50 %, with a median follow-up of half a year. Today within an oral presentation at 10:00 a These data are getting featured.m. CT at the Annual Getting together with of the American Culture of Clinical Oncology being held in Chicago.The process had began on the facial skin and scalp and progressed over his trunk and hands and subsequently to his hip and legs. His palms and soles were covered by a thick level of keratin with an orange hue. There is no previous background of a similar episode. The patient was not on any medications. The skin biopsies showed a thickened epidermis and a loose laminated stratum corneum with retained nuclei . The underlying dermis demonstrated a scant infiltrate of lymphocytes lacking atypia ..